Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
April 27, 2022 06:00 ET
|
Novartis Pharma AG
RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with...
Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten
April 26, 2022 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im ersten Quartal um +5% (kWk1, +1% USD), das operative Kernergebnis wuchs um +9% (kWk, +3% USD) Innovative Medicines (IM) steigerte den Umsatz...
Novartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme
April 26, 2022 01:00 ET
|
Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires du T1 en hausse de +5% (tcc1, +1% USD) et résultat opérationnel core en progression de 9% (tcc, +3% USD) Innovative Medicines (IM):...
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
April 26, 2022 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core...
Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
April 14, 2022 01:15 ET
|
Novartis Pharma AG
Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does...
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
April 05, 2022 20:29 ET
|
Novartis Pharma AG
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by...
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
April 05, 2022 01:15 ET
|
Novartis Pharma AG
Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration...
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
March 23, 2022 16:19 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive...
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
March 13, 2022 19:00 ET
|
Novartis Pharma AG
Children with three copies of SMN2 treated presymptomatically achieved age-appropriate milestones, including standing and walking; required no ventilatory or feeding tube support; and had no serious,...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
March 04, 2022 09:19 ET
|
Novartis Pharma AG
Les actionnaires approuvent la 25e augmentation consécutive du dividende qui passe à CHF 3.10 (+3,3%) par action pour 2021; représentant un rendement de 3.9%1 et une distribution du free cash-flow...